Breast cancer has historically been a disease for which immunotherapy was largely
unavailable. Recently, the use of immune checkpoint inhibitors (ICIs) in combination with …

Immune checkpoint inhibitors (ICIs) have led to durable clinical remissions in many
metastatic cancers. However, the single-agent efficacy of ICIs in breast cancer is low …

Immunotherapy is currently approved for a subset of patients diagnosed with advanced triple
negative breast cancer (TNBC), based on the phase III randomized controlled trial …

The advent of immunotherapy, particularly immune checkpoint inhibitors (ICIs), has
revolutionized the treatment of solid tumor malignancies. In breast cancer, the most robust …

Recent progress in immunobiology has led the way to successful host immunity
enhancement against breast cancer. In triple-negative breast cancer, the combination of …

Highlights•TNBCs is one of the most heterogenous form of breast cancer appear to have
elevated numbers of immune cells infiltration.•Using immune checkpoint inhibitors (ICIs) …

Simple Summary For decades, countless efforts have been devoted to developing targeted
drugs to improve the prognosis of triple-negative breast cancer (TNBC). Among the novel …

Abstract Purpose of Review To critically review the existing evidence on immune checkpoint
inhibitors (ICIs) in early-stage and metastatic breast cancer and discuss emerging strategies …

Immunotherapy comprises a promising new era in cancer therapy. Immune checkpoint
inhibitors targeting either the programmed death (PD)-1 receptor or its ligand PD-L1 were …

Introduction Immunotherapy has revolutionized cancer treatment, including TNBC, which
has limited options of treatment and poor prognosis. ICIs studied in TNBC include …